Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Formoterol in clinical practice - safety issues
Autore:
Rabe, KF;
Indirizzi:
Leiden Univ, Med Ctr, Dept Pulmonol, NL-2333 ZA Leiden, Netherlands LeidenUniv Leiden Netherlands NL-2333 ZA NL-2333 ZA Leiden, Netherlands
Titolo Testata:
RESPIRATORY MEDICINE
, volume: 95, anno: 2001, supplemento:, B
pagine: S21 - S25
SICI:
0954-6111(200108)95:<S21:FICP-S>2.0.ZU;2-7
Fonte:
ISI
Lingua:
ENG
Soggetto:
ASTHMATIC-PATIENTS; BRONCHIAL-ASTHMA; BETA(2)-ADRENOCEPTOR POLYMORPHISM; INHALED FORMOTEROL; HEALTHY-SUBJECTS; BETA-AGONISTS; SALMETEROL; SALBUTAMOL; BRONCHOCONSTRICTION; EXACERBATIONS;
Keywords:
Oxis (R); formoterol; safety; systemic effects; tolerance;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Rabe, KF Leiden Univ, Med Ctr, Dept Pulmonol, C3-P,Albinusdreef 2, NL-2333ZA Leiden, Netherlands Leiden Univ C3-P,Albinusdreef 2 Leiden NetherlandsNL-2333 ZA ds
Citazione:
K.F. Rabe, "Formoterol in clinical practice - safety issues", RESP MED, 95, 2001, pp. S21-S25

Abstract

While short-acting beta (2)-agonists are seen as the cornerstone of treatment as relief medication for asthma, current guidelines recommend long-acting beta (2)-agonists as maintenance therapy in combination with inhaled corticosteroids in patients with moderate to severe asthma, poorly controlled on present treatment. Although evidence has shown that formoterol, with itsfast- and long-acting profile, is effective when used both as regular and as-needed therapy in all types of asthma, there has been some concern aboutthe potential of beta (2)-agonists with long-acting profiles to produce side effects with a longer duration than seen with short-acting beta (2)-agonists. Also, where formoterol is used as needed, a higher total daily dose would be anticipated than when taken twice daily for regular maintenance therapy and this again has led to some concern. In a number of studies, formoterol has been shown to be well tolerated, and although systemic effects expected with this class of drugs did occur, formoterol had significantly lesseffect on serum potassium, pulse, blood pressure, cardiac frequency and QTinterval compared with terbutaline. In addition. the duration of effects was equivalent to that observed with terbutaline and salbutamol and the relative therapeutic index of formoterol compared with salbutamol was found to be 2.5. Furthermore, studies looking at long-term use of formoterol have shown there is no reduction in bronchodilatory effect. and thus, no development of tolerance. In conclusion, formoterol is well tolerated in high doses,producing side effects typical of its class, but with a duration no longerthan occurs with short-acting beta2-agonists. These observations, and the lack of tolerance development, suggest that formoterol may be appropriate treatment for patients with asthma of all types and severities on an as-needed basis or as regular treatment, (C) 2001 Harcourt Publishers Ltd.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/01/20 alle ore 12:24:48